In addition, the FDA and EMA recently approved the B-cell maturation antigen (BCMA)-targeting antibody-drug conjugate, belantamab mafodotin, for the treatment of patients with advanced, heavily pretreated, MM [12]. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.